<DOC>
	<DOCNO>NCT00004871</DOCNO>
	<brief_summary>RATIONALE : Azacitidine plus phenylbutyrate may help leukemia cell develop normal white blood cell . PURPOSE : Phase I trial study effectiveness combine azacitidine phenylbutyrate treat patient acute myeloid leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>Azacitidine Plus Phenylbutyrate Treating Patients With Acute Myeloid Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety toxicity azacitidine combination phenylbutyrate patient recurrent , refractory , untreated acute myeloid leukemia myelodysplastic syndrome . - Determine minimal effective pharmacologic dose azacitidine require consistently inhibit DNA methyltransferase patient population . - Obtain preliminary clinical and/or laboratory data suggest potential therapeutic activity combination regimen patient . OUTLINE : This dose deescalation study azacitidine . Patients receive azacitidine subcutaneously daily day 1-5 29-33 follow phenylbutyrate IV continuously day 5-12 33-40 . Treatment continue least 2 course absence disease progression . Patients responsive disease may receive additional 2 month therapy . Cohorts 3-6 patient receive deescalating dos azacitidine minimal effective pharmacologic dose ( MEPD ) determine . The MEPD define dose dose 1 6 patient meet target enzyme inhibition great 90 % . Once MEPD toxicity establish 5 day schedule , daily dose schedule azacitidine increase 10 , 14 , 21 day , follow phenylbutyrate 7 day . Courses repeat every 28 day . PROJECTED ACCRUAL : Approximately 32 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm myelodysplastic syndrome ( MDS ) indicate one following : Refractory anemia ( RA ) Primary refractory leukopenia thrombocytopenia MDS morphology RA excess blast ( RAEB ) RA ring sideroblast ( RARS ) Chronic myelomonocytic leukemia RAEB transformation RA RARS must least one follow : Absolute neutrophil count le 1,000/mm^3 Untransfused hemoglobin le 8 g/dL Platelet count le 20,000/mm^3 Anemia Thrombocytopenia require transfusion High risk chromosomal abnormality Any stage MDS allow include : Previously untreated MDS Refractory MDS allow failure achieve remission follow prior intensive chemotherapy least 1 month ago Relapsed , refractory , untreated acute myeloid leukemia ( AML ) following : WBC le 30,000/mm^3 Stable least 2 week Unlikely require cytotoxic therapy study Untreated AML poor risk factor response standard therapy include : Greater 60 year old AML occur set antecedent hematologic disorder High risk chromosome ( e.g. , abnormalities chromosome 5 7 complex cytogenetic abnormality ) Medical condition preclude cytotoxic chemotherapy primary therapy Refusal cytotoxic chemotherapy allow No clinical evidence CNS leukostasis CNS leukemia PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hemoglobin least 8 g/dL ( transfusion allow ) Hepatic : Bilirubin le 2.0 mg/dL ( unless due hemolysis Gilbert 's disease ) Renal : Creatinine le 2.0 mg/dL Cardiovascular : No disseminated intravascular coagulation Pulmonary : No pulmonary leukostasis Other : No active infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 week prior , 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior biologic therapy include colony stimulate factor recover Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy recover Endocrine therapy : At least 3 week since prior hormonal therapy recover Radiotherapy : At least 3 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
</DOC>